Retirement of the Principal Investigator

The trial will utilize Nutraceuticals (Vitamin D 2000IU oral once daily, Vitamin B6 100 mg oral once daily, Vitamin B12 100 mcg oral once daily, Omega-3 Fatty Acids 900 mg oral three times a day) in patients treated with Docetacel as Neoadjuvant or Adjuvant Breast cancer Therapy. The trial is being conducted to see if the use of Nutraceuticals will prevent or reduce Chemotherapy Induced Peripheral Neuropathy (CIPN).

Phase 2, Single Centre, Open-label 2 Arm Randomized Trial. The intervention group will receive a daily dose of Vitamin D, Omega-3-fatty acids, Vitamin B6, and Vitamin B12. The reference group will have usual care.

Dose of Nutraceuticals: Vitamin D 2000 IU oral once daily, Vitamin B6 100 mg oral once daily, Vitamin B12 100 mcg oral once daily, Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)

Population: Breast Cancer patients undergoing either neoadjuvant or adjuvant therapy with docetaxel.

106 participants in total will be needed with accrual being completed in hopefully 1 years' time. Study Investigators will screen the candidates for the study.

Inclusion Criteria:

• Female 18-70 years of age
• Biopsy proven invasive breast carcinoma
• Scheduled to receive docetaxel (3-6 cycles)
• Have values for liver (AST, ALT, Bilirubin) and renal function (CREAT), within 1.5 times normal values as drawn per standard of care.
• ECOG 0-2
• Be able to provide informed consent
• Willingness to adhere to regimen

Exclusion Criteria:

• Metastatic disease
• Any peripheral neuropathy
• Known HIV (testing not required)
• Diseases causing malabsorption i.e.: Inflammatory Bowel Disease, Celiac and Whipple's Disease
• Patients with seafood allergies
• Patients on Warfarin or with a documented clinically significant bleeding disorder